Research Article

Synergy between Vitamin D3 and Toll-Like Receptor Agonists Regulates Human Dendritic Cell Response during Maturation

Anne Brosbøl-Ravnborg, Bettina Bundgaard, and Per Höllsberg

Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark

Correspondence should be addressed to Per Höllsberg; ph@microbiology.au.dk

Received 1 March 2013; Accepted 18 March 2013

Academic Editor: Mohamad Mohty

Copyright © 2013 Anne Brosbøl-Ravnborg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human dendritic cells (DC) can be differentiated from blood monocytes in the presence of GM-CSF and IL-4 and matured by lipopolysaccharide (LPS). Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86. We here examine the function of vitamin D3 during DC maturation. One of the earliest changes to LPS-induced maturation was an increase in CD83 expression. Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12. The synergy occurred at concentrations where neither vitamin D3 nor the TLR agonists alone induced measurable cytokine secretion. Both LPS and PGN enhanced the level of the vitamin D3 receptor (VDR). Taken together, these data demonstrated that vitamin D3 and TLR agonists acted in synergy to alter secretion of cytokines from human DC in a direction that may provide an anti-inflammatory environment.

1. Introduction

Dendritic cells (DC) are highly specialized, professional antigen-presenting cells (APC) that orchestrate the immune response via integration of a variety of signals [1]. Immunosuppressive and anti-inflammatory compounds like IL-10 [2], 1α,25-dihydroxyvitamin D3 [3–5], and TGF-β [6] induce DC with tolerogenic properties in vitro. These DC are generally characterized by an immature or semimature phenotype, with low expression of costimulatory molecules. In addition, tolerogenic DC produce low amounts of proinflammatory cytokines and high amounts of anti-inflammatory cytokines.

Interactions between DC and regulatory T cells (Treg) facilitate the immunosuppression, immature DC induce Treg, and vice versa Treg prepare DC to become immunosuppressive [7, 8].

The biological active form of vitamin D is mediated by the active hormonal form 1α,25-dihydroxyvitamin D3 (hereafter referred to as vitamin D3). Its intracellular transcriptional effects are mediated through binding to the vitamin D receptor (VDR), which subsequently functions as a transcription factor. VDR is constitutively expressed in APC, such as macrophages and DC, and is inducible in activated T lymphocytes [9–11].

Several studies have demonstrated immunosuppressive effects of vitamin D3 on the functions of DC. In vitro maturation of both human and mouse DC in presence of vitamin D3 lead to reduced expression of MHC-II and the costimulatory molecules CD40, CD80, and CD86 resulting in an enhanced production of IL-10 and a reduced secretion of IL-12 [12, 13].

Vitamin D3 deficiency has been associated with a higher rate of several diseases, including multiple sclerosis (MS) [14, 15]. Moreover, administration of vitamin D3 in the animal model experimental autoimmune encephalitis (EAE) suppressed the development and progression of disease [16], and vitamin D3 has also been shown to ameliorate several other models of autoimmune diseases [17, 18].

Infection with Gram-negative bacteria provides lipopolysaccharide (LPS), which contains pathogen-associated molecular patterns (PAMP) that function as a Toll-like receptor (TLR) ligand. LPS is detected by TLR4 and is one of the major components used for inducing maturation of monocyte-derived DC in vitro [19]. TLR are expressed by
many APC and activate an intracellular signaling pathway that leads to transcriptional activation of proinflammatory genes and innate effector molecules [20].

It is feasible that PAMP and TLR ligands interfere with vitamin D3 functions in the immune system. This would be consistent with the fact that individuals with severe vitamin D3 deficiencies have an increase susceptibility to intracellular infections [21]. A recent study shows that the influence of vitamin D3 on TLR4 ligand-induced activation of APC is dependent on the order of VDR and TLR4 engagement [9]. To further study the interplay between TLR agonists and vitamin D3, we examined the maturation and cytokine profile of DC differentiated in vitro from human peripheral blood monocytes.

2. Materials and Methods

2.1. Ethical Approval. The study was conducted in accordance with the Ethical Declaration of Helsinki. The project was approved by the local Ethics Committee on Biomedical Research Ethics (j. no20090210).

2.2. Isolation of Peripheral Blood Mononuclear Cells. Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats (Blood bank, Aarhus University Hospital, Skejby, Denmark) of healthy donors using Ficoll-Paque PLUS (GE Healthcare BioScience AB, Uppsala, Sweden) with density gradient centrifugation according to the manufacturer’s procedure. PBMC were cryopreserved in 90% heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich, Saint Louis, USA) supplemented with 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Saint Louis, USA) supplemented with 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Saint Louis, MO, USA) at a concentration of 107 cells/mL and stored at −80°C until use.

2.3. Isolation of CD14+ Monocytes by EasySep Negative Selection. For the isolation of monocytes, PBMC were rapidly thawed and resuspended in phosphate-buffered saline (PBS) supplemented with 2% FBS and 1 mM EDTA. From these cells, monocytes were purified by negative immunomagnetic depletion using the EasySep Human Monocyte Enrichment Kit according to manufacturer’s instructions (cat. no 19059, Stemcell Technologies, Grenoble, France). In brief, cells were resuspended at a concentration of 5 × 107 in PBS (without Mg2+ and Ca2+) + 2% FBS + 1 mM EDTA. First, cells were labeled with EasySep Human Monocyte Enrichment Cocktail for 10 min at 4°C, and then the EasySep D Magnetic Particles for Monocytes were incubated with the cell suspension for 5 min at 4°C. Finally, the suspension was placed into the EasySep Magnet, and the desired negatively selected untouched monocytes were collected. To increase purity, the magnetic isolation procedure was repeated once, and the harvested cells were kept cold. The purity of the untouched monocytes was evaluated by flow cytometry for CD14 expression. Cells were collected and labeled with FITC-conjugated mouse anti-CD14 monoclonal antibody (TUK4, DAKO Denmark A/S, Glostrup, Denmark). Cell populations were analyzed on a Cytomics FC500 flow cytometer (Beckman-Coulter) and with FlowJo software (Tree Star, Ashland, USA). The purity ranged from 85 to 95% (data not shown).

2.4. Generation of Monocyte-Derived Dendritic Cells. The purified monocytes were washed twice and cultured in 6-well plates (Techno Plastic Products) at a density of 0.5–0.7 × 106 cells/mL in 1.2 mL of RPMI 1640 medium (Gibco, LifeTechnologies, UK) supplemented with 2% normal human serum type AB (NHS AB), 2 mM glutamine, and 20 µg/mL gentamicin (Gibco). The cultures were established in the presence of 100 ng/mL recombinant human GM-CSF (Bayer Healthcare AG, Leverkusen, Germany or Peprotech, London, UK) and 20 ng/mL recombinant human IL-4 (Immunotools GmbH, Friesoythe, Germany). The plates were incubated at 37°C with 5% CO2 for six days. On day 3, the cultures were supplemented with 360 µL fresh medium supplemented with 100 ng/mL GM-CSF and 20 ng/mL IL-4. On day 5, 1.56 mL fresh medium supplemented with 100 ng/mL GM-CSF and 20 ng/mL IL-4 was added to the cultures together with 0, 20, or 100 nM of 1α,25-dihydroxyvitamin D3 (Sigma-Aldrich) as indicated. On day 6, either mock (medium), bacterial LPS (E. coli OIII:B4, LPS ultrapure cat. no. tlr3-pelps, InvivoGen, San Diego, USA) in concentrations of 0, 0.01, 0.1, 1, 10, or 100 ng/mL, or PGN (from S. aureus, cat. no. tlr-pgnsa, InvivoGen) in concentrations of 0, 0.1, 0.5, 1, 5, or 10µg/mL was added during the last 24 hrs of culture. On day 7, all supernatants were collected and frozen at −70°C and all cells were harvested for subsequent phenotypic and functional analyses.

2.5. Morphological Examination. In order to examine the morphological maturation of the cells, viability and morphology were evaluated by light microscopy (Leica Microsystems) of the cells in the 6-well plates at a magnification of ×10 or ×40 prior to harvest.

2.6. Flow Cytometric Analyses. Harvested cells were washed twice in PBS and resuspended in 100 µL PBS supplemented with 0.5% bovine albumin serum (BSA) and 0.1% sodium azide for staining. Cells were incubated for 10 min at room temperature with an Fc receptor blocking solution (BioLegend, San Diego, USA). Next, cells were incubated at 4°C for 30 min with the following monoclonal mouse-anti-human antibodies (mAb): anti-HLA-DR FITC (L243, BD Biosciences), anti-CD14 FITC (TUK4, DAKO), anti-CD40 PE (5C3, BD Biosciences), anti-CD80 PE (MAB104, Beckman Coulter), anti-CD83 PE-Cy5 (HB15e, BD Biosciences), and anti-CD86 PE-Cy5 (2331 FUN-1, BD Biosciences). After staining, cells were washed twice in PBS supplemented with 0.5% BSA and 0.1% sodium azide and resuspended in PBS with 0.99% paraformaldehyde. Flow cytometry was performed on a Cytomics FC-500 flow cytometer (Beckman Coulter), and all subsequent analyses were made in FlowJo software (Tree Star).

2.7. Quantification of Cytokines. For cytokine assessment, supernatants from DC cultures were thawed and centrifuged shortly and the content of IL-6, IL-8, IL-10, and IL-12p70...
was measured with enzyme-linked immunosorbent assay (ELISA). Concentrations of IL-6, IL-8, IL-10, and IL-12p70 were measured using Duoset ELISA kits (R&D Systems) according to the manufacturer's instructions. The spectrophotometer Versamax ELISA microplate reader (Molecular Devices, LLC, Sunnyvale, USA) and Softmax Pro software (Molecular Devices) were used to measure and analyze the samples.

2.8. Western Blotting Analysis/Cell Lysis and Immunoblotting. Whole-cell extracts were prepared using 1× lysis buffer (Cell Signaling Technology, Beverly, MA, USA) supplemented with 1 mM PMSF, 5 mM NaF, and Complete Mini Protease Inhibitor (Roche Diagnostics, Basel, Switzerland) at a concentration recommended by the manufacturer. Lysates were centrifuged at 2,600 × g for 5 min, followed by 20,000 × g for 10 min, and whole-cell extracts were immediately frozen at −70°C. Proteins were separated in XT Criterion 12% gels (BioRad Laboratories Inc, Hercules, CA, USA) using XT MOPS running buffer (Bio-Rad) for 1 h and 30 min at 175 V and subsequently transferred to nitrocellulose membranes for 1 h and 45 min at 300 mA. Detection of VDR was performed using anti-VDR mAb (sc-13133) (Santa Cruz Biotechnology Inc, Dallas, TX, USA) diluted 1:1,000, and GAPDH was detected using anti-GAPDH antibody (Santa Cruz Biotechnology) diluted 1: 2,000. All antibodies were diluted in 5% skimmed milk in TBS with 0.1% Tween-20. Ponceau-S staining was performed as a loading control. Immunoblots were developed using Super Signal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Rockford, IL, USA).

3. Results

3.1. LPS Induces Rapid Maturation of DC, Which Is Inhibited by Vitamin D3. As expected, vitamin D3 added 24 hrs prior to LPS treatment inhibited LPS-induced maturation measured by the expression of surface molecules 24 hrs after the addition of LPS (Figure 1(a)). Conversely, vitamin D3 prevented the downregulation of CD14 expression, indicating a block in maturation of immature DC (Figure 1(a)). To further explore the kinetics, cells were examined 4 hrs after addition of LPS. In the absence of vitamin D3, DC had already upregulated CD83 and downregulated CD14 after 4 hrs of LPS treatment, whereas only minor or no changes were observed for HLA-DR, CD80, CD86, and CD40. Thus, upregulation of CD83 appears to be an early event during DC maturation. The presence of vitamin D3 partially inhibited upregulation of CD83 almost to the same degree as observed after 24 hrs.

The early induction of DC maturation was morphologically visible as dendritic formations as early as 4 hrs after the addition of LPS, but more pronounced after 24 hrs. The presence of vitamin D3 inhibited the outgrowth of these processes (Figure 1(b)).

3.2. Vitamin D3 Is Necessary for LPS-Induced Secretion of IL-6, IL-8, and IL-10. The presence of vitamin D3 inhibited the maturation of differentiated DC. To examine whether vitamin D3 influenced the cytokine secretion induced by LPS, differentiated DC were treated with various concentrations of LPS and monitored for the secretion of IL-6, IL-8, and IL-10 in the absence or presence of either 20 or 100 nM vitamin D3. These concentrations of vitamin D3 did not induce cytokine secretion from DC. Although LPS induced a dose-dependent secretion of IL-6, IL-8, and IL-10, the presence of vitamin D3 was able to further enhance this secretion (Figures 2(a)–2(c)). Importantly, at low doses of LPS, cytokines were only induced in the presence of vitamin D3, despite the fact that neither LPS alone nor vitamin D3 alone induced measurable cytokines. These data demonstrated that vitamin D3 acted in synergy with LPS to induce the secretion of IL-6, IL-8, and IL-10.

3.3. Vitamin D3 Inhibits LPS-Induced IL-12 Secretion. Since vitamin D3 is thought to inhibit the proinflammatory response, we next examined whether IL-12, a cytokine that promotes a Th1-like response, was affected by vitamin D3. The presence of LPS at concentrations above 1 ng/mL induced high levels of IL-12p70 (Figure 2(d)). In the presence of either 20 or 100 nM vitamin D3, the detection of LPS-induced IL-12p70 was completely abolished. This demonstrated that vitamin D3 is a potent inhibitor of IL-12.

3.4. Vitamin D3 Is Necessary for PGN-Induced Secretion of IL-6, IL-8, and IL-10. To test whether LPS was the only TLR ligand able to induce cytokines and act in synergy with vitamin D3, differentiated DC were treated with the TLR2 agonist PGN. PGN was able to induce high levels of IL-8 and low levels of IL-6 and IL-10 at high concentrations of PGN (Figures 3(a)–3(c)). However, in the presence of vitamin D3, PGN-induced cytokine secretion from differentiated DC was synergistically increased for IL-6, IL-8, and IL-10 (Figures 3(a)–3(c)). In contrast to LPS, PGN did not induce IL-12 (Figure 3(d)). This indicated that PGN, similar to LPS, induced cytokine secretion from DC in synergy with vitamin D3.

3.5. LPS and PGN Enhance Expression of the Vitamin D Receptor. Vitamin D3 exerts its function after binding to an intracellular receptor, VDR. To examine whether LPS could increase the sensitivity of DC for vitamin D3, the protein level of VDR was measured by western blotting. In the absence of vitamin D3 or TLR agonists, a low level of VDR was detectable (Figure 4). However, the presence of LPS or PGN increased the level of VDR, which was not further affected by the presence of vitamin D3 (Figure 4). This indicated that LPS or PGN was able to enhance the sensitivity of DC for vitamin D3 by increasing the expression of its receptor.

4. Discussion

The generation of Treg is in part controlled by the maturation of DC. In mice, treatment with vitamin D3 induces a regulatory T-cell profile with increased expression of IL-10, TGF-β, FoxP3, and CTLA-4 and a significant reduction of IL-12p70, IL-23p19, IL-6, and IL-17 [22]. We also observed...
that vitamin D$_3$ promoted a regulatory profile, promoting IL-10 and inhibiting IL-12p70. Surprisingly, we found that in synergy with LPS or PGN, vitamin D$_3$ increased IL-6 in cultures of differentiated DC. Whether the detection of IL-6 indicates a pro- or an anti-inflammatory profile is, however, not clear. IL-6 may be associated with a soluble form of the IL-6 receptor and this complex may mediate proinflammatory reactions through a process known as transsignaling [23]. Blockade of IL-6 transsignaling completely protected gp130/F/F knock-in mutant mice from LPS hypersensitivity, suggesting cross-talk between JAK/STAT and TLR pathways [24]. On the other hand, the classical binding of IL-6 to gp130/IL-6 receptor complexes on the cell surface may promote anti-inflammatory/regenerative reactions [23]. Thus, further investigations may elucidate which one of these scenarios is supported by vitamin D$_3$.

Importantly, we found that, at very low levels of LPS, vitamin D$_3$ promoted the secretion of IL-8 in synergy with LPS. That is, neither the concentration of 0.01 ng/mL of LPS nor the presence of vitamin D$_3$ alone was able to induce this cytokine. However, when added together, vitamin D$_3$ and LPS acted in synergy and induced in the order of 2–4 ng of IL-8. IL-8 is a major chemoattractant for the recruitment of polymorphonuclear leukocytes that serve as part of the first
Figure 2: Vitamin D₃ is necessary for LPS-induced secretion of IL-6, IL-8, and IL-10. DC were stimulated with 0, 20, or 100 nM of vitamin D₃ (vitamin D) and 10-fold dilutions of LPS (from 100 to 0.01 ng/mL). Cell-culture supernatants were assessed for IL-6 (a), IL-8 (b), IL-10 (c), and IL-12 (d) by ELISA. Experiment is representative of at least two independent experiments.

Line of defense against intruding bacteria. This emphasizes that besides its effect on the adaptive immune system, vitamin D₃ also has important functions for the innate immune response.

IL-8 has previously been shown to be induced by the transformed cell line THP-1 in the presence of vitamin D₃ and agonists of TLR2, TLR3, TLR4, NOD1, and NOD2 [25]. However, other studies have reported that vitamin D₃ inhibited IL-8 production in response to IL-1α in human peripheral blood mononuclear cells, keratinocytes, and fibroblasts [26, 27], although TLR and IL-1R are both signals through MyD88. Inhibition of IL-8 by vitamin D₃ has also been observed in primary cultures of human periodontal ligament cells stimulated with P. gingivalis, a Gram-negative bacteria containing LPS [28]. Thus, the cell type, the presence of other cytokines, and potentially virulence factors from microorganisms may all be important for modulating the control exerted by vitamin D₃ on IL-8 secretion.

Although LPS is frequently used to mature monocyte-derived human DC, other TLR agonist may serve the same functions. LPS is a component of the outer membrane of the Gram-negative bacterial cell wall, whereas Gram-positive bacteria are characterized by a cell wall containing PGN, a ligand for TLR2. In agreement with the observed functions of LPS, PGN also acted in synergy with vitamin D₃ for the secretion of IL-6, IL-8, and IL-10 but was unable to induce IL-12p70 as did LPS. This indicates that PGN from Gram-positive bacteria may also have the ability to prime the response towards a regulatory T-cell profile and that PGN also induces chemoattractants for recruiting polymorphonuclear leukocytes.
The level of VDR in part determines the sensitivity of DC for vitamin D₃. Liu et al. found that the *M. tuberculosis*-derived lipopeptide, which is a TLR2/1 ligand, induced the expression of VDR. In addition, they observed that vitamin D₃ upregulated the antimicrobial peptide cathelicidin, which is important for the killing of intracellular bacteria [19]. However, since most bacteria are extracellular, we examined the general Gram-negative and Gram-positive TLR ligands: LPS (TLR4) and PGN (TLR2). We found that these TLR ligands were also able to increase the level of VDR. The shifting by vitamin D₃ of the immune response towards a regulatory profile as opposed to a proinflammatory response may be of benefit for the invading microorganisms. In this view, the upregulation of VDR by both LPS and PGN may further enhance the effect of vitamin D₃ and thus further prevent the antimicrobial defense. The inhibition of IL-8 induction by *P. gingivalis* [28], as mentioned previously, further indicates that the microorganism may have evolved mechanisms to avoid part of these host innate responses. Whether this is a general feature remains to be investigated. Conversely, we speculate that these effects of vitamin D₃ may also prevent unnecessary inflammatory reactions towards commensal microorganisms present in the gut. The shifting towards a regulatory profile by vitamin D₃ may also be of benefit during graft-versus-host disease (GVHD) [29]. However, whether the anti-inflammatory actions of vitamin D₃ can be enhanced in an *in vivo* setting by the addition of low levels of TLR agonists remains to be examined.
5. Conclusions

In conclusion, human DC maturation is inhibited by vitamin D$_3$. LPS and PGN (TLR4 and TLR2 agonists) increase the level of VDR and act in synergy with vitamin D$_3$ for induction of IL-6, IL-8, and IL-10, whereas LPS induction of IL-12 is inhibited by vitamin D$_3$. PGN does not induce measurable IL-12. Thus, vitamin D$_3$ synergizes with TLR agonists in modulating human DC cytokine secretion during maturation. This may generate an anti-inflammatory environment that favors the induction of regulatory cells.

Acknowledgment

This work was supported by grants from the Danish Multiple Sclerosis Society and the Faculty of Health, Aarhus University.

References

[1] J. Banchereau and R. M. Steinman, "Dendritic cells and the control of immunity," *Nature*, vol. 392, no. 6673, pp. 245–252, 1998.
[2] K. Steinbrink, M. Wölll, H. Jonuleit, J. Knop, and A. H. Enk, "Induction of tolerance by IL-10-treated dendritic cells," *The Journal of Immunology*, vol. 159, no. 10, pp. 4772–4780, 1997.
[3] L. Piemonti, P. Monti, M. Sironi et al., "Vitamin D$_3$ affects differentiation, maturation, and function of human monocyte-derived dendritic cells," *The Journal of Immunology*, vol. 164, no. 9, pp. 4443–4451, 2000.
[4] G. Penna and L. Adorini, "1α,25-dihydroxyvitamin D$_3$ inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation," *The Journal of Immunology*, vol. 164, no. 5, pp. 2405–2411, 2000.
[5] W. W. J. Unger, S. Laban, F. S. Kleijwegt, A. R. Van Der Slik, and B. O. Roep, "Induction of Treg by monocyte-derived DC modulated by vitamin D$_3$ or dexamethasone: differential role for PD-L1," *European Journal of Immunology*, vol. 39, no. 11, pp. 3147–3159, 2009.
[6] H. Torres-Aguilar, S. R. Aguilar-Ruiz, G. González-Pérez et al., "Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4$^+$ T cells," *The Journal of Immunology*, vol. 184, no. 4, pp. 1765–1775, 2010.
[7] K. Mahnke, T. S. Johnson, S. Ring, and A. H. Enk, "Tolerogenic dendritic cells and regulatory T cells: a two-way relationship," *Journal of Dermatological Science*, vol. 46, no. 3, pp. 159–167, 2007.
[8] R. A. Maldonado and U. H. von Andrian, "How tolerogenic dendritic cells induce regulatory T cells," *Advances in Immunology*, vol. 108, pp. 111–165, 2010.
[9] V. Gambhir, J. Kim, S. Siddiqui et al., "Influence of 1,25-dihydroxyvitamin D$_3$ on TLR4-induced activation of antigen presenting cells is dependent on the order of receptor engagement," *Immunobiology*, vol. 216, no. 9, pp. 988–996, 2011.
[10] C. M. Veldman, M. T. Cantorna, and H. F. DeLuca, "Expression of 1,25-dihydroxyvitamin D$_3$ receptor in the immune system," *Archives of Biochemistry and Biophysics*, vol. 374, no. 2, pp. 334–338, 2000.
[11] G. Penna, S. Amuchastegui, N. Giarratana et al., "1,25-dihydroxyvitamin D$_3$ selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells," *The Journal of Immunology*, vol. 178, no. 1, pp. 145–153, 2007.
[12] K. Sochorová, V. Budinký, D. Rožková et al., "Paricalcitol (19-nor-1,25-dihydroxyvitamin D$_3$) and calcitriol (1,25-dihydroxyvitamin D$_3$) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells," *Clinical Immunology*, vol. 133, no. 1, pp. 69–77, 2009.
[13] E. van Etten and C. Mathieu, "Immunoregulation by 1,25-dihydroxyvitamin D$_3$: basic concepts," *Journal of Steroid Biochemistry and Molecular Biology*, vol. 97, no. 1-2, pp. 93–101, 2005.
[14] A. Ascherio, K. L. Munger, and K. C. Simon, "Vitamin D and multiple sclerosis," *The Lancet Neurology*, vol. 9, no. 6, pp. 599–612, 2010.
[15] F. Baake, T. Takiishi, H. Korf, C. Gysemans, and C. Mathieu, "Vitamin D$_3$ modulator of the immune system," *Current Opinion in Pharmacology*, vol. 10, no. 4, pp. 482–496, 2010.
[16] K. M. Spach, F. E. Nashold, B. N. Dittel, and C. E. Hayes, "IL-10 signaling is essential for 1,25-dihydroxyvitamin D 3-mediated..."
inhibition of experimental autoimmune encephalomyelitis,” The Journal of Immunology, vol. 177, no. 9, pp. 6030–6037, 2006.

[17] C. Mathieu and L. Adorini, “The coming of age of 1,25-dihydroxyvitamin D₃ analogs as immunomodulatory agents,” Trends in Molecular Medicine, vol. 8, no. 4, pp. 174–179, 2002.

[18] L. Adorini and G. Penna, “Control of autoimmune diseases by the vitamin D endocrine system,” Nature Clinical Practice Rheumatology, vol. 4, no. 8, pp. 404–412, 2008.

[19] P. T. Liu, S. Stenger, H. Li et al., “Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response,” Science, vol. 311, no. 5768, pp. 1770–1773, 2006.

[20] T. Kawai and S. Akira, “Pathogen recognition with Toll-like receptors,” Current Opinion in Immunology, vol. 17, no. 4, pp. 338–344, 2005.

[21] W. R. Berrington and T. R. Hawn, “Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?” Immunological Reviews, vol. 219, no. 1, pp. 167–186, 2007.

[22] C. Daniel, N. A. Sartory, N. Zahn, H. H. Radeke, and J. M. Stein, “Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 1, pp. 23–33, 2008.

[23] J. Scheller, A. Chalaris, D. Schmidt-Arras, and S. Rose-John, “The pro- and anti-inflammatory properties of the cytokine interleukin-6,” Biochimica et Biophysica Acta, vol. 1813, no. 5, pp. 878–888, 2011.

[24] C. J. Greenhill, S. Rose-John, R. Lissilaa et al., “IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3,” The Journal of Immunology, vol. 186, no. 2, pp. 1199–1208, 2011.

[25] T. Ikeuchi, T. Nakamura, S. Fukumoto, and H. Takada, “A vitamin D₃ analog augmented interleukin-8 production by human monocytic cells in response to various microbe-related synthetic ligands, especially NOD2 agonistic muramylpeptide,” International Immunopharmacology, vol. 15, no. 1, pp. 15–22, 2013.

[26] C. G. Larsen, M. Kristensen, K. Paludan et al., “1,25(OH)₂-D₃ is a potent regulator of interleukin-1 induced interleukin-8 expression and production,” Biochemical and Biophysical Research Communications, vol. 176, no. 3, pp. 1020–1026, 1991.

[27] J. L. Riis, C. Johansen, B. Gesser et al., “1α,25(OH)₂-D₃ regulates NF-κB DNA binding activity in cultured normal human keratinocytes through an increase in lck expression,” Archives of Dermatological Research, vol. 296, no. 5, pp. 195–202, 2004.

[28] X. Tang, Y. Pan, and Y. Zhao, “Vitamin D inhibits the expression of interleukin-8 in human periodontal ligament cells stimulated with Porphyromonas gingivalis,” Archives of Oral Biology, vol. 58, no. 4, pp. 397–407, 2012.

[29] M. Benrashid, K. Moyers, M. Mohty, and B. N. Savani, “Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: implication for preventive therapy,” Experimental Hematology, vol. 40, pp. 263–267, 2012.